Search - tctmd.com

Displaying 81 - 100 of 213

Presentation TCT 2018

Low Surgical Risk Aortic Stenosis In The Us: The Patient Really Wants TAVR

Presenter: Vinayak Bapat, Susheel K. Kodali, Philippe Genereux, Martin B. Leon, Scott Lim, Michael J. Mack, Raj Makkar, Patrick T. O'Gara, Michael J. Reardon, Allan Schwartz

September 23, 2018

Presentation TCT 2018

Program Update: The LOTUS TAVR System

Presenter: Michael J. Reardon

September 22, 2018

Presentation TCT 2018

My Crystal Ball - Predicting the Role of Surgery and Surgeons in the Treatment of Aortic Stenosis Once the Cycle of Low-Risk Studies is Completed

Presenter: Allan Schwartz, Stephan Windecker, Michael J. Reardon

September 22, 2018

Presentation TCT 2018

TCT-15: Two-Year Outcomes After Transcatheter Aortic Valve Replacement With Mechanically- versus Self-Expandable Valves: Results From The REPRISE III Randomized Trial

Presenter: Charles J. Davidson, Jeffrey J. Popma, Michael J. Reardon

September 21, 2018

News Daily News

TAVR’s Two-Surgeon Sign-off Rule Must Go, Experts Say

Shelley Wood

July 23, 2018

News Daily News

Hemodynamic Deterioration Post-SAVR: Dysmetabolic Profile, Calcification Could Be Early Warning Signs

Caitlin E. Cox

July 10, 2018

Presentation The Structural Heart Disease Summit 2018

Counterpoint: Most Bicuspid Aortic Valves (Especially In Younger Low-Risk Patients) Will Remain in the Surgical Domain!

Presenter: Susheel K. Kodali, Michael J. Reardon, Patrick M. McCarthy

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Point: TAVR Will Be the Treatment of Choice for Bicuspid Aortic Valve Disease in the Future!

Presenter: Susheel K. Kodali, Michael J. Reardon, Mathew Williams

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Once the Cycle of Low-Risk Studies is Completed, Predicting the Role of Surgery and Surgeons in the Treatment of Aortic Stenosis

Presenter: Allan Schwartz, Stephan Windecker, Michael J. Reardon

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Case #3: A Small (Undersized) Surgical Bioprosthesis

Presenter: Michael J. Reardon, Adnan K. Chhatriwalla, Danny Dvir, Ariel Finkelstein, Kendra J. Grubb, Michael J. Mack, Thomas Modine, Mark J. Russo

June 21, 2018

News Conference News SCAI 2018

Debate Over Cerebral Protection in TAVR Fizzles in the Face of Reimbursement Hopes

Shelley Wood

April 28, 2018

News Daily News

New Surgical Valve Durability Data Set ‘Critical Benchmark’ for TAVR Devices

Yael L. Maxwell

March 26, 2018

News Conference News AHA 2017

DACAB: Ticagrelor and Aspirin Improve SVG Patency at 1 Year Post-CABG vs Monotherapy

Yael L. Maxwell

November 12, 2017

News Conference News TCT 2017

Selection Bias? Debate Asks How Many TAVR Devices Centers Should Stock

Yael L. Maxwell

November 09, 2017

Presentation TCT 2017

Point A Multi-Device Lesion-Specific Approach is Preferred!

Presenter: Michael J. Reardon

November 01, 2017

Presentation TCT 2017

The Compelling Saga of Stroke after TAVR: Key Messages From NeuroARC

Presenter: Michael J. Reardon, Didier Tchetche, Alexandra J. Lansky

October 31, 2017

Presentation TCT 2017

LOTUS TAVR Technology Review (Including EDGE) and Clinical Program Updates

Presenter: Michael J. Reardon

October 31, 2017

Presentation TCT 2017

Viewpoint #1: PARTNER 2A and SURTAVI are Convincing TAVR is Preferred in ALL (Appropriate) Intermediate-Risk Patients

Presenter: Michael J. Reardon

October 30, 2017

News Daily News

Hemodynamics of First-Gen Sapien Valve Hold Up Well Over the Years: PARTNER Analysis

Caitlin E. Cox

September 29, 2017

News Conference News TVT 2017

Reacting to REPRISE III: Enthusiasm, Explanations, and Caveats for the Lotus Pivotal TAVR Trial

Shelley Wood

June 16, 2017

Advertisement

Low Surgical Risk Aortic Stenosis In The Us: The Patient Really Wants TAVR

Program Update: The LOTUS TAVR System

My Crystal Ball - Predicting the Role of Surgery and Surgeons in the Treatment of Aortic Stenosis Once the Cycle of Low-Risk Studies is Completed

TCT-15: Two-Year Outcomes After Transcatheter Aortic Valve Replacement With Mechanically- versus Self-Expandable Valves: Results From The REPRISE III Randomized Trial

TAVR’s Two-Surgeon Sign-off Rule Must Go, Experts Say

Hemodynamic Deterioration Post-SAVR: Dysmetabolic Profile, Calcification Could Be Early Warning Signs

Counterpoint: Most Bicuspid Aortic Valves (Especially In Younger Low-Risk Patients) Will Remain in the Surgical Domain!

Point: TAVR Will Be the Treatment of Choice for Bicuspid Aortic Valve Disease in the Future!

Once the Cycle of Low-Risk Studies is Completed, Predicting the Role of Surgery and Surgeons in the Treatment of Aortic Stenosis

Case #3: A Small (Undersized) Surgical Bioprosthesis

Debate Over Cerebral Protection in TAVR Fizzles in the Face of Reimbursement Hopes

New Surgical Valve Durability Data Set ‘Critical Benchmark’ for TAVR Devices

DACAB: Ticagrelor and Aspirin Improve SVG Patency at 1 Year Post-CABG vs Monotherapy

Selection Bias? Debate Asks How Many TAVR Devices Centers Should Stock

Point A Multi-Device Lesion-Specific Approach is Preferred!

The Compelling Saga of Stroke after TAVR: Key Messages From NeuroARC

LOTUS TAVR Technology Review (Including EDGE) and Clinical Program Updates

Viewpoint #1: PARTNER 2A and SURTAVI are Convincing TAVR is Preferred in ALL (Appropriate) Intermediate-Risk Patients

Hemodynamics of First-Gen Sapien Valve Hold Up Well Over the Years: PARTNER Analysis

Reacting to REPRISE III: Enthusiasm, Explanations, and Caveats for the Lotus Pivotal TAVR Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content